CoreMedic
Thomas Bauer has a strong background in the medical device industry, with experience ranging from research and development to general management. Currently serving as the CEO/CTO/Managing Director at CoreMedic, as well as the CEO and Co-Founder at GalloMedic GmbH, Thomas is involved in developing innovative technologies for structural heart therapies. With previous roles at companies like Medtronic and Invatec, Thomas has demonstrated leadership in operations, product development, and research. Thomas holds an MBA in International Business Management and a degree in Medical Engineering.
This person is not in any teams
This person is not in any offices
CoreMedic
CoreMedic was initiated in 2012 as a spin-out of the Heart Center of University of Bern, Switzerland, in order to develop an innovative treatment concept for mitral valve regurgitation (MR). The initiators of CoreMedic had a simple but challenging idea: to combine the least invasive treatment option for MR, replacement of mitral chords, and theleast invasive operational procedure into one new system: ChordArt.In 2017, the development of ChordArt had progressed towards first use in a human trial, enabling CoreMedic to attract institutional financing. The company moved to RIZ-innovation center at Radolfzell, Germany, located at Lake Constance close to the Swiss border within the leading medical technology cluster of Tuttlingen, Germany.Following successful conclusion of the first human trial of ChordArt in 2018, and two-year data confirming the powerful treatment effect of the ChordArt implant in patients with severe MR, CoreMedic GmbH is tirelessly working to make the ChordArt TMVr system available to patients.